Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 3, 2014, Pages 274-278

  Puentes, Fabiola ^a   Topping, Joanne ^a   Kuhle, Jens ^a   Van Der Star, Baukje J ^b   Douiri, Abdel ^c   Giovannoni, Gavin ^a   Baker, David ^a   Amor, Sandra ^a,b   Malaspina, Andrea ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d North East London and Essex MND Care and Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL ANTIGEN; CYTOSKELETON ANTIGEN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOREACTIVITY; LIGHT CHAIN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RATING SCALE; SEQUENCE HOMOLOGY; SURVIVAL RATE; UPREGULATION;

ALS;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; RILUZOLE;

EID: 84896718498     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305494     Document Type: Article

References (23)

1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
2. Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135:847-52.
3. Turner MR, Bakker M, Sham P, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:15-21. (Pubitemid 34705122)
4. Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467-72.
5. Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-6. (Pubitemid 43739759)
6. Zetterberg H, Jacobsson J, Rosengren L, et al. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-33. (Pubitemid 350135296)
7. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561-7.
8. Lu CH, Petzold A, Kalmar B, et al. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 2012;7:e40998.
9. Lu CH, Kalmar B, Malaspina A, et al. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods 2011;195:143-50.
10. Couratier P, Yi FH, Preud'homme JL, et al. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 1998;154:137-45. (Pubitemid 28156929)
11. Fialova L, Svarcova J, Bartos A, et al. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur J Neurol 2010;17:562-6.
12. Fialova L, Bartos A, Soukupova J, et al. Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. Folia Biol (Praha) 2009;55:23-6.
13. Fialova L, Svarcova J, Bartos A, et al. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol (Praha) 2012;57:415-19.
14. Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998;50:768-72.
15. Huizinga R, van der Star BJ, Kipp M, et al. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012;60:422-31.
16. Huizinga R, Heijmans N, Schubert P, et al. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007;66:295-304. (Pubitemid 46559022)
17. Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011;117:528-37.
18. Gnanapavan S, Grant D, Pryce G, et al. Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity 2012;45:298-303.
19. Zhang X, Chen S, Li L, et al. Decreased level of 5- methyltetrahydrofolate: a potential biomarker for pre-symptomatic amyotrophic lateral sclerosis. J Neurol Sci 2010;293:102-5.
20. van Blitterswijk M, Gulati S, Smoot E, et al. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12:430-8.
21. Beers DR, Zhao W, Liao B, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun 2011;25:1025-35.
22. Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, et al. Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. J Neurol 2005;252:772-81. (Pubitemid 40984851)
23. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91. (Pubitemid 24065791)